Cambridge Investment Research Advisors Inc. Has $762,000 Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cambridge Investment Research Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) by 29.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,782 shares of the specialty pharmaceutical company’s stock after buying an additional 1,088 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Jazz Pharmaceuticals were worth $762,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in JAZZ. Pacer Advisors Inc. lifted its position in Jazz Pharmaceuticals by 12,168.8% during the 4th quarter. Pacer Advisors Inc. now owns 340,460 shares of the specialty pharmaceutical company’s stock worth $54,239,000 after buying an additional 337,685 shares in the last quarter. Prudential Financial Inc. lifted its position in Jazz Pharmaceuticals by 3,731.5% during the 3rd quarter. Prudential Financial Inc. now owns 311,383 shares of the specialty pharmaceutical company’s stock valued at $41,503,000 after purchasing an additional 303,256 shares during the period. Wellington Management Group LLP lifted its position in Jazz Pharmaceuticals by 7.5% during the 1st quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock valued at $408,654,000 after purchasing an additional 184,124 shares during the period. Todd Asset Management LLC lifted its position in Jazz Pharmaceuticals by 5,080.5% during the 3rd quarter. Todd Asset Management LLC now owns 174,012 shares of the specialty pharmaceutical company’s stock valued at $23,194,000 after purchasing an additional 170,653 shares during the period. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in Jazz Pharmaceuticals during the 3rd quarter valued at about $20,723,000. Institutional investors and hedge funds own 89.79% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Finbar Larkin sold 1,706 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $143.92, for a total value of $245,527.52. Following the completion of the transaction, the senior vice president now directly owns 23,854 shares of the company’s stock, valued at $3,433,067.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, SVP Finbar Larkin sold 1,706 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $143.92, for a total value of $245,527.52. Following the completion of the transaction, the senior vice president now directly owns 23,854 shares of the company’s stock, valued at $3,433,067.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Patricia Carr sold 1,023 shares of the firm’s stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $133.22, for a total transaction of $136,284.06. Following the completion of the transaction, the chief accounting officer now directly owns 6,286 shares of the company’s stock, valued at $837,420.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,580 shares of company stock valued at $2,127,210. 4.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

JAZZ has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $204.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, March 6th. StockNews.com initiated coverage on shares of Jazz Pharmaceuticals in a research report on Thursday, May 18th. They set a “strong-buy” rating on the stock. Royal Bank of Canada cut their target price on shares of Jazz Pharmaceuticals from $207.00 to $202.00 in a research report on Thursday, May 11th. Needham & Company LLC increased their price target on shares of Jazz Pharmaceuticals from $205.00 to $212.00 in a research report on Thursday, May 11th. Finally, The Goldman Sachs Group increased their price target on shares of Jazz Pharmaceuticals from $190.00 to $212.00 and gave the company a “buy” rating in a research report on Friday, March 3rd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and an average target price of $200.75.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $132.93 on Tuesday. The stock has a market capitalization of $8.51 billion, a P/E ratio of -52.33, a P/E/G ratio of 0.76 and a beta of 0.75. Jazz Pharmaceuticals plc has a twelve month low of $125.36 and a twelve month high of $163.31. The company has a 50 day moving average of $140.31 and a 200-day moving average of $147.47. The company has a quick ratio of 2.32, a current ratio of 3.06 and a debt-to-equity ratio of 1.71.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last issued its quarterly earnings results on Wednesday, March 1st. The specialty pharmaceutical company reported ($0.84) earnings per share for the quarter. Jazz Pharmaceuticals had a positive return on equity of 24.72% and a negative net margin of 4.18%. The business had revenue of $972.12 million for the quarter, compared to the consensus estimate of $972.70 million. As a group, equities research analysts forecast that Jazz Pharmaceuticals plc will post 14.68 EPS for the current fiscal year.

About Jazz Pharmaceuticals

(Get Rating)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio.